|
|
||||||||
AJP - Heart and Circulatory Physiology, Vol 271, Issue 6 2283-H2289, Copyright © 1996 by American Physiological Society
ARTICLES |
P. H. McNulty, A. Darling and J. M. Whiting
Section of Cardiology, Veterans Affairs Connecticut Medical Center, West Haven 06516, USA.
Ischemic preconditioning depletes the myocardium of glycogen, thus blunting lactic acidosis during subsequent episodes of ischemia. Preconditioning also protects against reperfusion arrhythmias and infarction. To test whether glycogen depletion is necessary for this ischemic tolerance, we preconditioned two groups of intact rats with a series of 3-min coronary artery occlusions. In one group, preconditioning lowered the glycogen concentration of the ischemic region by approximately 50% (24.9 +/- 2.5 to 12.5 +/- 1.8 mumol/g; P < 0.01). In the other, the heart was first loaded with glycogen via glucose-insulin infusion so that preconditioning merely reduced its glycogen concentration back to normal physiological levels. Compared with nonpreconditioned control rats, preconditioned rats with both normal and subnormal glycogen concentrations were protected from reperfusion arrhythmias after a 6-min coronary occlusion (incidence: control rats, 100%; normal glycogen rats, 11%; reduced glycogen rats, 11%). In contrast, only rats with subnormal glycogen concentration after preconditioning exhibited reduced lactate formation and infarct size after a 45-min coronary occlusion [infarct size (percentage of risk area): control rats, 53 +/- 10%; normal glycogen rats, 50 +/- 16%, P = not significant; subnormal glycogen rats, 18 +/- 10%, P < 0.01]. Thus, in the intact rat, myocardial glycogen depletion appears to be necessary for the infarct-limiting, but not for the antiarrhythmic, effects of ischemic preconditioning.
This article has been cited by other articles:
![]() |
Y. Wu, H. Wang, D. L. Brautigan, and Z. Liu Activation of glycogen synthase in myocardium induced by intermittent hypoxia is much lower in fasted than in fed rats Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E469 - E475. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Tracey, J. L. Treadway, W. P. Magee, J. C. Sutt, R. K. McPherson, C. B. Levy, D. E. Wilder, L. J. Yu, Y. Chen, R. M. Shanker, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1177 - H1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schulz, M. V Cohen, M. Behrends, J. M Downey, and G. Heusch Signal transduction of ischemic preconditioning Cardiovasc Res, November 1, 2001; 52(2): 181 - 198. [Full Text] [PDF] |
||||
![]() |
W. R. Tracey, W. P. Magee, C. A. Ellery, J. T. MacAndrew, A. H. Smith, D. R. Knight, and P. J. Oates Aldose reductase inhibition alone or combined with an adenosine A3 agonist reduces ischemic myocardial injury Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1447 - H1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. McNulty, D. Jagasia, J. M. Whiting, and T. Caulin-Glaser Effect of 6-wk estrogen withdrawal or replacement on myocardial ischemic tolerance in rats Am J Physiol Heart Circ Physiol, April 1, 2000; 278(4): H1030 - H1034. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |